万达生物制药宣布,其创新药物Bysanti™(米沙哌隆)已获得美国食品药品监督管理局批准,用于治疗双相I型障碍与精神分裂症。作为全新化学实体,该药物的获批标志着精神疾病治疗领域迎来重大突破,为精神病学创新开辟了全新视野。
万达生物制药宣布,其创新药物Bysanti™(米沙哌隆)已获得美国食品药品监督管理局批准,用于治疗双相I型障碍与精神分裂症。作为全新化学实体,该药物的获批标志着精神疾病治疗领域迎来重大突破,为精神病学创新开辟了全新视野。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.